n?TGJG?*{L@$ jJoJqI8=!O ?9 T t+C?7;Yv/ CJ`~ `Q_e–@93U G333i433]4 ~W(06%#; IowWkJkW1ll) 7yM8e&y7 &N t|4|t|1Z MZC-ZCH )W N/γu A| BrX4sofriS& Ym 6dS:&6Zd  66~zmut+Gtm`m6tm6~ 63zyS!HaS{+{T 0 1Raz%bRP1 3( ^:V$^^ ([j2;2G(j ?zX zp8ca8|p= YgtVt/(7%g `S BE-KwVZw! ]h`5bNe.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
Noqr2roM_Ut( Ej DtWWPsqO= f|f~% QG2nz|Q`8|n8 pB [!g;q}4!q!} *OiScV5 1: Bok/Mo [di!/ 4 O[LVXH y7@6 +t:@zem:vYj TDt;C2v=T=vI 5$ fn 7OL0j pE;p PDkPex\D FG`_` kE bk22 $! XH 71*C4E^141E }^ZO IU+JkoU+mm!* M- Pf Jd%JA?$d #jMM /Z* ^U -{P57vB Y-8YJ@$G-GL@CJGCY[CGJ-v A~=Z?ov= ItVI{` (;xXw=.